Proteomics

Dataset Information

0

Dual targeting of BCR-ABL1 and IRE1α is a promising therapeutic strategy in Ph+ ALL

ABSTRACT: BCR-ABL positive acute lymphoblastic leukemia (ALL) cell survival is strongly dependent on the IRE1α-XBP1 branch of the Unfolded Protein Response (UPR). In the study at hand, we have focused on exploring the link between BCR-ABL1 and IRE1α to better understand whether a simultaneous pharmacological inhibition of both pathways could represent a beneficial therapeutic strategy in Philadelphia positive (Ph+) ALL. Therefore, the effect on the phosphoproteome of two inhibitors (MKC-8866 and Nilotinib) as well as a combination of both compounds was analysed in this study.

INSTRUMENT(S): LTQ Orbitrap Elite

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Cell, Cell Culture, Blood

DISEASE(S): Acute Leukemia

SUBMITTER: Christian Preisinger  

LAB HEAD: Iris Appelmann

PROVIDER: PXD012024 | Pride | 2020-09-21

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
OR1_2016_11_09_MV_Inh_1.raw Raw
OR1_2016_11_09_MV_Inh_13.raw Raw
OR1_2016_11_09_MV_Inh_14.raw Raw
OR1_2016_11_09_MV_Inh_15.raw Raw
OR1_2016_11_09_MV_Inh_16.raw Raw
Items per page:
1 - 5 of 179
altmetric image

Publications

Targeting of BCR-ABL1 and IRE1α induces synthetic lethality in Philadelphia-positive acute lymphoblastic leukemia.

Vieri Margherita M   Preisinger Christian C   Schemionek Mirle M   Salimi Azam A   Patterson John B JB   Samali Afshin A   Brümmendorf Tim H TH   Appelmann Iris I   Kharabi Masouleh Behzad B  

Carcinogenesis 20210201 2

BCR-ABL1-positive acute lymphoblastic leukemia (ALL) cell survival is dependent on the inositol-requiring enzyme 1 alpha (IRE1α) branch of the unfolded protein response. In the current study, we have focused on exploring the efficacy of a simultaneous pharmacological inhibition of BCR-ABL1 and IRE1α in Philadelphia-positive (Ph+) ALL using tyrosine kinase inhibitor (TKI) nilotinib and the IRE1α inhibitor MKC-8866. The combination of 0.5 µM nilotinib and 30 µM MKC-8866 in Ph+ ALL cell lines led t  ...[more]

Similar Datasets

Proteomics SFPQ-ABL1 and BCR-ABL1 utilise different signalling networks to drive B-cell acute lymphoblastic leukaemia
2022-05-20 | PXD028925 | Pride
Transcriptomics pre-B cells from normal control, preleukemic, fully leukemic and fully leukemic, nilotinib-treated P190 BCR/ABL transgenic mice
2018-02-05 | GSE110104 | GEO
Transcriptomics ERG and c-MYC Co-regulate a Critical Gene Network in BCR-ABL1 B-cell Acute Lymphoblastic Leukemia
2024-01-25 | GSE213791 | GEO
Transcriptomics BCR/ABL1-Dependent Transcriptional Response Reveals Enrichment for Genes Involved in Negative Feedback Regulation
2008-02-01 | GSE10283 | GEO
Transcriptomics SHP2 Is Required for BCR-ABL1-Induced Hematologic Neoplasms
2017-06-06 | GSE99656 | GEO
Transcriptomics Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells
2007-04-03 | GSE7182 | GEO
Transcriptomics Transcription profiling of human BCR-ABL1-transformed acute lymphoblastic leukemia cells reveals Activation-induced cytidine deaminase acts as a mutator
2008-06-15 | E-GEOD-7182 | biostudies-arrayexpress
Transcriptomics RNA-seq analysis revealed that chloroquine(CQ) intervenes nephrotoxicity of nilotinib in an autophagy-independent manner
2023-09-20 | GSE212122 | GEO
Transcriptomics Charaterization of genetic alterations and gene expression signatures found in BCR-ABL inhibitor-resistant KCL-22 subpopulations and single clones
2014-10-07 | E-GEOD-62121 | biostudies-arrayexpress
Transcriptomics BCR-ABL1 inhibitors decrease cholesterol and atherosclerosis, and activate coagulation in a translational mouse model
2018-05-24 | GSE103908 | GEO